Julio Rosenstock, MD, FACE, is the lead author of an article published today in the Oxford University Press’ Endocrine Reviews Journal. Reviewing data from Phase 2 clinical trials for basal insulins icodec and efsitora, as well as the Phase 3 icodec program, the article indicates that once-weekly insulins provide comparable glycemic control to once-daily analogues, with a … Read more
Paul Evans, President and CEO and Nadege Gunn, MD, CPI, Medical Director and Senior Scientific Advisor for Velocity are highlighted in a recent article by the ACRP, The Year Ahead in Trends, Challenges, and Opportunities for Clinical Trial Sites. In the article, Dr. Gunn shares her hope for Sponsors and CROs “to fund a long-term … Read more
Watch Christy Godwin and Laura Falcone discuss Velocity’s unique ‘Demand and Delivery’ approach. Christy and Laura work in unison to ensure full alignment among what Sponsors and CROs demand, and the quality, performance, and patient experiences Velocity delivers. In this video, they delve into: The importance of understanding goals and translating them into actionable strategies … Read more
Velocity Clinical Research, the leading multi-specialty clinical sites business, has launched its VISION technology platform to transform the way patients access and participate in clinical trials. Velocity’s VISION technology unifies patient experience and recruitment capabilities across nearly 100 locations globally. The AI-driven platform includes VISION Engage, a patient-focused mobile application that has had 30,000 downloads … Read more
A staggering 80% of clinical trials are delayed or shut down due to enrollment challenges, with half of those delays occurring at the site level. Two-thirds of principal investigators leave research after conducting a single trial. It’s time for a change. Watch Paul Evans, Nick Campbell, Nick Spittal, and Craig Koch discuss Velocity’s unique model, … Read more
Velocity Clinical Research, the leading multi-specialty clinical sites organization, today announces its further expansion in Europe, adding five sites in Poland after acquiring multi-site network KO-MED Centra Kliniczne and two in Germany, having acquired The Pulmonary Research Institute at the LungenClinic Grosshansdorf and KLB Gesundheitsforschung Lübeck. Velocity’s growth is accelerating across Europe, with 17 locations … Read more
Velocity has made an incredible impact over the past year! Our sites conducted clinical trials that supported 12 U.S. product approvals in 2023, contributing to the betterment of global health. To date, Velocity has contributed to research programs for over 50 product approvals. From pioneering vaccines to cutting-edge drugs, Velocity’s team worldwide has worked diligently … Read more
Velocity Clinical Research is committed to inclusivity and ensuring that everyone, regardless of their nationality or spoken language, can participate in groundbreaking clinical research studies. Language should never be a barrier to advancing medicine, and so, in collaboration with Boostlingo, we offer live phone and video interpretation services in over 300 languages. This includes American … Read more
Velocity Clinical Research, the leading multi-specialty clinical sites business, announced it has expanded into Poland, acquiring its first site, ClinMedica Research. Located in Skierniewice, which is halfway between Warsaw and Lodz, the site marks the first in a series of key acquisitions targeted by the company in Poland by year’s end. In addition to being … Read more
Julio Rosenstock, MD, FACE, joined the American Diabetes Association’s Diabetes Core Update podcast to discuss propound results from a recently published JAMA article, “Tirzepatide vs Insulin Lispro Added to Basal Insulin in Type 2 Diabetes.” The study indicated that once weekly tirzepatide with insulin glargine may have the potential to change the standard of care … Read more